We are live on ! Find out more
RNAM

Avidity Biosciences

Delisted

RNAM was delisted on the 26th of February, 2026.

144 hedge funds and large institutions have $701M invested in Avidity Biosciences in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $756K | Put options by funds: $345K

34% more capital invested

Capital invested by funds: $522M → $701M (+$179M)

13% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 47

1% more funds holding

Funds holding: 142144 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5.84% less ownership

Funds ownership: 110.3%104.46% (-5.8%)

Holders
144
Holders Change
+2
Holders Change %
+1.41%
% of All Funds
2.1%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
53
Reduced
47
Closed
23
Calls
$756K
Puts
$345K
Net Calls
+$411K
Net Calls Change
-$176K
Name Holding Trade Value Shares
Change
Change in
Stake
DTL
76
Dynamic Technology Lab
Singapore
$478K +$188K +28,160 +114%
MCP
77
Mirador Capital Partners
California
$476K +$242K +36,195 +221%
AA
78
ALPS Advisors
Colorado
$459K -$27.1K -4,057 -7%
CS
79
Credit Suisse
Switzerland
$455K -$38.7K -5,795 -10%
Mitsubishi UFJ Asset Management
80
Mitsubishi UFJ Asset Management
Japan
$394K +$105K +15,654 +61%
SG Americas Securities
81
SG Americas Securities
New York
$377K +$279K +41,705 New
D.E. Shaw & Co
82
D.E. Shaw & Co
New York
$375K -$747K -111,793 -73%
NRD
83
Nebula Research & Development
New York
$340K +$251K +37,587 New
MIM
84
MetLife Investment Management
New Jersey
$338K
AIG
85
American International Group
New York
$333K +$9.94K +1,487 +4%
EGM
86
Engineers Gate Manager
New York
$321K +$237K +35,520 New
PA
87
Profund Advisors
Maryland
$296K -$153K -22,961 -41%
HCA
88
Harbor Capital Advisors
Illinois
$293K +$15.6K +2,336 +8%
SEI Investments
89
SEI Investments
Pennsylvania
$287K
JWCA
90
J.W. Cole Advisors
Florida
$283K +$209K +31,292 New
CC
91
Corton Capital
Ontario, Canada
$269K +$31.1K +4,654 +19%
NL
92
NWAM LLC
Washington
$265K -$42.6K -6,372 -18%
VOYA Investment Management
93
VOYA Investment Management
Georgia
$265K -$157K -23,504 -45%
Janus Henderson Group
94
Janus Henderson Group
United Kingdom
$236K -$254 -38 -0.1%
Royal Bank of Canada
95
Royal Bank of Canada
Ontario, Canada
$217K +$79.3K +11,856 +98%
A
96
AlphaQuest
New York
$211K +$156K +23,264 New
HF
97
HRT Financial
New York
$202K -$668K -99,863 -82%
TRCT
98
Tower Research Capital (TRC)
New York
$195K +$124K +18,533 +613%
Acadian Asset Management
99
Acadian Asset Management
Massachusetts
$191K +$141K +21,162 New
State Board of Administration of Florida Retirement System
100
State Board of Administration of Florida Retirement System
Florida
$183K

RNAM Hedge Fund Activity: Q4 2023 in Review

144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2023, worth a combined $701M — up 34% from $522M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 23 closed out — a net gain of 2 holders — while 53 added to existing stakes and 47 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12.2M. The largest seller was RA Capital Management, cutting an estimated $26.5M.

  • 144 institutional investors held Avidity Biosciences (RNAM) as of Q4 2023, up from 142 in Q3 2023.
  • Funds reported $701M of Avidity Biosciences stock for Q4 2023, up 34% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q4 2023 and 23 closed out, a net change of +2 holders.
  • The largest Avidity Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.2M added.
  • The largest Avidity Biosciences seller in Q4 2023 was RA Capital Management, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2023.